General Information of Drug (ID: DMA01BV)

Drug Name
S-18986 Drug Info
Synonyms
S 18986; S-18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Discontinued in Phase 2 [1]
Therapeutic Class
Neurodegenerative
Cross-matching ID
PubChem CID
637863
CAS Number
CAS 175340-20-2
TTD Drug ID
DMA01BV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Halothane DM80OZ5 Anaesthesia 9A78.6 Approved [3]
E-2007 DMJDYNQ Diabetic neuropathy 8C0Z Approved [4]
Zopiclone DMPI6Z0 Insomnia 7A00-7A0Z Approved [5]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [6]
Enflurane DM0YJSB Anaesthesia 9A78.6 Approved [7]
Isoflurane DMY6T31 Anaesthesia 9A78.6 Approved [8]
Bromazepam DMY9TCW Anxiety disorder 6B00-6B0Z Approved [9]
Artemisinin SP DMFETDK Malaria 1F40-1F45 Approved [10]
Dihydroergotoxine DM5D6WZ Alzheimer disease 8A20 Approved [11]
Barbiturate DMJIA6T Anaesthesia 9A78.6 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4304).
2 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3 Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
6 Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
7 Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
8 Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
9 Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
10 GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
11 Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
12 Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.